TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 56,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 56,000 shares of TransMedics Group stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total transaction of $6,475,280.00. Following the transaction, the chief executive officer now owns 74,087 shares of the company’s stock, valued at $8,566,679.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

TransMedics Group Stock Up 2.9 %

TMDX stock opened at $127.99 on Friday. The stock has a market cap of $4.19 billion, a P/E ratio of -376.44 and a beta of 1.87. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The stock’s fifty day simple moving average is $85.54 and its two-hundred day simple moving average is $76.85. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $129.66.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The business’s revenue for the quarter was up 132.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.08) EPS. Analysts expect that TransMedics Group, Inc. will post 0.54 EPS for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on TMDX. Morgan Stanley lifted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Oppenheimer lifted their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday. TD Cowen lifted their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Canaccord Genuity Group increased their target price on shares of TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and an average target price of $119.00.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds have recently modified their holdings of TMDX. Harbour Capital Advisors LLC grew its holdings in TransMedics Group by 1.7% during the fourth quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares during the period. RiverPark Advisors LLC lifted its position in shares of TransMedics Group by 19.5% during the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after buying an additional 215 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after acquiring an additional 222 shares during the period. Park Avenue Securities LLC increased its holdings in TransMedics Group by 3.4% in the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock worth $841,000 after acquiring an additional 372 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new stake in TransMedics Group in the 1st quarter valued at about $30,000. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.